Detalhe da pesquisa
1.
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models.
Gastric Cancer
; 27(3): 473-483, 2024 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38261067
2.
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
J Hepatol
; 72(6): 1159-1169, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31954205
3.
Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis.
J Hepatol
; 69(3): 635-643, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29758334
4.
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
Cancer Res
; 83(10): 1699-1710, 2023 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129948
5.
Nrf2 in Neoplastic and Non-Neoplastic Liver Diseases.
Cancers (Basel)
; 12(10)2020 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33053665
6.
Distinct Mechanisms Are Responsible for Nrf2-Keap1 Pathway Activation at Different Stages of Rat Hepatocarcinogenesis.
Cancers (Basel)
; 12(8)2020 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32824383